No Data
Express News | sichuan hexie shuangma: Completes a 1.596 billion yuan equity acquisition with business registration change.
Sichuan Hexie Shuangma (000935): The acquisition progress exceeds expectations, and the company is embarking on new growth poles.
This report overview: the company's acquisition of pharmaceutical assets has progressed beyond expectations. In the future, the company is expected to rely on its own deep cultivation of private equity in the pharmaceutical sector to drive the continued rapid development of Shenzhen Jianyuan, with promising future growth. Investment Highlights: maintaining a "shareholding" rating.
Sichuan Hexie Shuangma (000935): Investment turning negative drags down performance, acquisition of assets layout in pharmaceuticals.
This report outlines: The company's investment business turning negative resulted in a significant decline in performance, acquiring Shenzhen Jianyuan to seize the growth opportunities in the biomedical industry, the new fund successfully completed fundraising leading to an increase in management fee income, and the improvement in capital markets benefiting the company's project exits. Investment Highlights: Maintaining
Sichuan Shuangma: Report for the third quarter of 2024
Sichuan Hexie Shuangma (000935.SZ) released its performance for the first three quarters, with a net income of 0.245 billion yuan, a year-on-year decrease of 63.41%.
sichuan hexie shuangma (000935.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved revenue...
Express News | Three mergers in a single day! The merger and reorganization market remains active, showing four major new trends.
No Data
No Data